Ketamine: all studies (page 101) - The Consciousness Library

Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.

Clinical Pharmacology & Therapeutics February 1, 2025 Ksenia A Vekhova, Eugenia D Namiot, Jörgen Jonsson et al. 43 citations

Ketamine has a long and very eventful pharmacological history. Its enantiomer, esketamine ((S)-ketamine), was approved by the US Food and Drug Administration (FDA) and EMA for patients with treatment-resistant depression (TRD) in 2019. The number of approved indications for ketamine and esketamine continues to increase, as well as the number of clinical trials. This analysis provides a...

DOI: 10.1002/cpt.3478 Full text Esketamine. Drug. Clinical trials. Research. +8

Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway.

Biological Psychiatry February 1, 2025 Cassiano Ricardo Alves Faria Diniz, Ana Paula Crestani, Plinio Cabrera Casarotto et al. 15 citations

Diverse antidepressants were recently described to bind to TrkB (tyrosine kinase B) and drive a positive allosteric modulation of endogenous BDNF (brain-derived neurotrophic factor). Although neurotrophins such as BDNF can bind to p75NTR (p75 neurotrophin receptor), their precursors are the high-affinity p75NTR ligands. While part of an unrelated receptor family capable of inducing completely...

DOI: 10.1016/j.biopsych.2024.06.021 Full text Ketamine Neuroplasticity Binding Extinction memory +12

How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.

International Journal of Mental Health Nursing February 1, 2025 Melanie Trimmel, Antonia Renner, Alexander Kaltenboeck 4 citations

Ketamine treatment has shown promising effects for different mental disorders. Yet, little is known on how people who receive ketamine for a psychiatric problem subjectively experience undergoing this intervention. We conducted a systematic literature search to identify relevant qualitative research on the first-person experience of undergoing ketamine treatment in a psychiatric context. 24...

DOI: 10.1111/inm.13425 Full text Ketamine Psychedelic therapy First‐person perspective Lived experience +7

Effect of ketamine on task-based functional magnetic resonance imaging findings in major depressive disorder: A mini-review.

Journal of Affective Disorders February 1, 2025 Farzaneh Ramezani, Peyman Mardani, Fatemeh Nemati et al. 4 citations

Over the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its...

DOI: 10.1016/j.jad.2024.10.118 Full text Major depressive disorder Mood disorders Task-Based FMRI Ketamine therapy +4

Acute effects of esketamine on hypoxic ventilatory response, haemodynamics, and brain function in healthy volunteers.

British Journal of Anaesthesia February 1, 2025 Simone C Jansen, Monique van Velzen, Elise Sarton et al. 11 citations

The acute hypoxic ventilatory response is a critical chemoreflex originating at the carotid bodies. This study investigates the impact of low-dose i.v. esketamine on the ventilatory response to 20 min of isocapnic hypoxia to test the hypothesis that esketamine does not affect hypoxic ventilation. In this open-label study, 18 healthy subjects received a 3-h escalating i.v. infusion of...

DOI: 10.1016/j.bja.2024.08.040 Full text Esketamine Haemodynamics Hypoxic ventilatory response Anesthesia +4

Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.

European Neuropsychopharmacology February 1, 2025 Danica E. Johnson, Nelson B Rodrigues, Sydney Weisz et al.

Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients...

DOI: 10.1016/j.euroneuro.2024.11.008 Full text Depressive disorder Post-traumatic Stress disorders Treatment-resistant +5

Ketamine treatment in youth for fast reduction of suicidality and engagement in psychotherapy: A randomized placebo-controlled trial protocol.

Contemporary Clinical Trials February 1, 2025 Noreen A Reilly-Harrington, Tatiana Falcone, David A Jobes et al.

Suicide is a leading cause of death in young persons. While ketamine has demonstrated rapid anti-suicidal effects, its safety and efficacy in youth has not been fully investigated. The Collaborative Assessment and Management of Suicidality (CAMS), a suicide-focused treatment shown to decrease suicidal ideation and symptom distress, has never been studied in combination with ketamine. This study...

DOI: 10.1016/j.cct.2024.107777 Full text Adolescents Cams Psychotherapy Young adults +5

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Psychiatry Research February 1, 2025 Adam Bayes, Thanh Vinh Cao, Ana Rita Barreiros et al. 6 citations

Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD). Ketamine can give rise to acute, cumulative and longer-term side effects (SEs) across a treatment course. The Ketamine Side Effect Tool (KSET) examines adverse effects though its length has affected feasibility for use in clinical settings. To estimate the frequency...

DOI: 10.1016/j.psychres.2024.116334 Full text Adverse events Side-effects Tolerability Depression therapy +4

Systemic ketamine toxicity following dermal application of a compounded pain cream.

The American Journal of Emergency Medicine February 1, 2025 Skyler Kessler, Bernard Weigel, Ross Ellison et al. 5 citations

Ketamine is an NMDA receptor antagonist commonly used as a dissociative anesthetic and analgesic. Though it is conventionally administered via the intravenous, intramuscular, or intranasal route, use as a compounded analgesic cream is becoming increasingly common. This is a case report of a 61-year-old man who was detained by the police for erratic driving. He was transported to the emergency...

DOI: 10.1016/j.ajem.2024.12.031 Full text Dermal application Pain cream Ketamine toxicity Topical drug safety +3

Ketamine impairs the performance of male mice in novel recognition object test and reduces the immunoreactivity of GAD67 in the hippocampus: Role of pioglitazone.

Pharmacology, Biochemistry, and Behavior February 1, 2025 Talita Rodrigues, Getulio Nicola Bressan, Patrícia Zorzi Juliani et al.

Schizophrenia is a mental disorder characterized by positive, negative, and cognitive symptoms which is treated with antipsychotics. However, these drugs present several side effects and, some schizophrenia symptoms, like cognitive, are difficult to treat. The peroxisome proliferator-activated receptors-gamma (PPAR-γ) are expressed in dopaminergic neurons of the midbrain participating in the...

DOI: 10.1016/j.pbb.2024.173950 Full text Animal behavior Monoamine oxidase Open field Social interaction +6